Browsing by Author "ARRAZTOA, J"

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    CONSERVATIVE TREATMENT OF EARLY BREAST-CANCER
    (1988) BAEZA, MR; SOLE, J; LEON, A; ARRAZTOA, J; RODRIGUEZ, R; CLAURE, R; CORNEJO, S; CORNEJO, J
    At our institution, and treatment policy for early carcinoma of the breast (T1-2, NO, AJC) is lumpectomy followed by radiotherapy to the breast and peripheral lymphatics. From October 1976 until December 1982, 171 patients have been admitted and treated. Radiotherapy was administered with 60 Co, 5.000 cGy in 5 weeks to the breast and lymphatics plus a boost to the scar giving q.s.p. 6.400 cGy at maximum tumor depth. With a minimum followup of 3 years and a median follow-up of 61.7 months the locoregional control was 94.2% and survival at 8 years with no evidence of disease (NED) was 77.2% with an overall survival rate of 90%. No difference in NED survival rate was found between Stage I and II. There was a tendency to better survival rate in those patients older than 50 years and also for post menopausal patients, however the difference did not reach statistical significance (66.7% NED survival at 8 years for premenopausal and 81.8% NED survival for post menopausal, also at 8 years, p = 0.056 Gehan). The time elapsed between surgery and radiation therapy (between 1 and 2 months) was found to be nonsignificant. Only 1 out of 171 patients has had axillary dissection. The importance or lack of it, is discussed.
  • No Thumbnail Available
    Item
    IFOSFAMIDE TREATMENT OF ADVANCED OVARIAN-CANCER
    (1984) YAZIGI, R; WILD, R; MADRID, J; ARRAZTOA, J
    To determine the efficacy of ifosfamide in the treatment of advanced ovarian malignancy, 20 patients with stages III and IV epithelial ovarian cancer were treated with this agent. Of these, 15 received the drug as primary chemotherapy. The response rate was 33%, with a median duration of remission of 13 mo. Five patients were treated with ifosfamide after failure with previous chemotherapy; no responses were seen in this group. Hematuria was observed in 2% of the treatment cycles with the use of the antidote mercapto-ethan-sulfonate acid. Though ifosfamide is an active drug in the treatment of patients with advanced ovarian cancer, it is not superior to traditional single alkylating agents.